2015 American Transplant Congress
Incidence of CMV Viremia in Obese and Morbidly Obese Kidney Transplants Under a Low Dose Valganciclovir Prophylaxis Protocol
1Pharmacy Practice, Univ of IL-Chicago, Chicago, IL; 2Surgery, Univ of IL-Chicago, Chicago, IL.
Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to…2015 American Transplant Congress
Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis
Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal…2015 American Transplant Congress
Diabetic Kidney Transplant Recipients: Impaired Infection Control and Alloreactivity
New onset diabetes after transplant (NODAT) has been associated with an increased risk of infection and sepsis. Previous studies, however, failed to identify differences in…2015 American Transplant Congress
African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
Houston Methodist Hospital, Houston, TX.
Safe and effective use of low-dose (450 mg/day) valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in renal transplant recipients (RTRs) has been reported. However, it is…2015 American Transplant Congress
Recipient Immunity to Murine Cytomegalovirus Influences Natural Killer Cell Responses in Infected Renal Allografts
BACKGROUND: Human cytomegalovirus (CMV) is associated epidemiologically with renal allograft loss, but the impact of recipient CMV immunity upon graft survival is unclear. Natural killer…2015 American Transplant Congress
Recurrent Cytomegalovirus Infection After Solid Organ Transplant
University Health Network, Toronto, Canada.
Background:Cytomegalovirus is a common opportunistic infection after transplant. Relapse may occur after treatment of the initial episode of viremia or disease and secondary prophylaxis is…2015 American Transplant Congress
Epigenetic Reprogramming of Murine Cytomegalovirus Immediate Early Genes Induced By Renal Transplantation
Background: Reactivation of latent CMV is a significant infectious complication in solid organ transplant recipients. MCMV is a valuable model for studying molecular mechanisms controlling…2015 American Transplant Congress
Safety and Outcome of Ganciclovir-Resistant CMV Treated With Foscarnet: A Single Center Retrospective Study
Background: Infection with cytomegalovirus (CMV) is an important cause of morbidity and mortality following solid organ transplantation (SOT). Resistance can rarely develop via mutations in…2015 American Transplant Congress
A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis
Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…2015 American Transplant Congress
Implementation of Evidence-Based Guidelines for Cytomegalovirus Prevention in Pediatric Solid Organ Transplantation
Cincinnati Children's, Cincinnati.
Optimal strategies to prevent cytomegalovirus (CMV) disease after pediatric solid organ transplantation (SOT) in a cost effective manner are uncertain. We evaluated the frequency of…
American Transplant Congress abstracts